Literature DB >> 6317041

The interaction of carbamylated low-density lipoprotein with cultured cells. Studies with human fibroblasts, rat peritoneal macrophages and human monocyte-derived macrophages.

B Gonen, T Cole, K S Hahm.   

Abstract

We determined the effects of various degrees of chemical modification of low-density lipoprotein (LDL) on its interaction with receptors present on human fibroblasts, human monocyte-derived macrophages and rat peritoneal macrophages. We isolated LDL (d = 1.019-1.063 g/ml) and carbamylated different numbers of lysine residues and tested its cell-interactive properties, including binding, degradation, and stimulation of [3H]oleate incorporation into cholesteryl oleate. Small carbamylation of LDL (approximately 1-2% of lysine residues) resulted in a reduced ability (70-80% of control) to displace 125I-labeled LDL from fibroblast receptors. Modification of 12.5-25% of lysine residues resulted in a marked increase in the ability of LDL to interact with scavenger receptors and an almost total loss in the ability to interact with apolipoprotein B-E receptors. Acetylated LDL and malondialdehyde-modified LDL inhibited competitively the degradation of 125I-carbamylated LDL by human macrophages. Thus, the extent of modification plays an important role in recognition of modified LDL by scavenger receptors. There also seems to be a range of modification over which LDL is not yet recognized by the scavenger receptor, but its interaction with the apolipoprotein B-E receptor is markedly reduced. This perhaps explains how a small in vivo modification of LDL can result in an increase in residence time of LDL in the subendothelial tissue which can lead to further local interactions, ultimately increasing the atherogenicity of the LDL particle.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6317041     DOI: 10.1016/0005-2760(83)90162-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

Review 1.  Mechanisms and consequences of carbamoylation.

Authors:  Sigurd Delanghe; Joris R Delanghe; Reinhart Speeckaert; Wim Van Biesen; Marijn M Speeckaert
Journal:  Nat Rev Nephrol       Date:  2017-07-31       Impact factor: 28.314

2.  Interaction of 4-hydroxynonenal-modified low-density lipoproteins with the fibroblast apolipoprotein B/E receptor.

Authors:  W Jessup; G Jurgens; J Lang; H Esterbauer; R T Dean
Journal:  Biochem J       Date:  1986-02-15       Impact factor: 3.857

3.  Association of rheumatoid arthritis disease activity and antibodies to periodontal bacteria with serum lipoprotein profile in drug naive patients.

Authors:  Aulikki Kononoff; Pia Elfving; Pirkko Pussinen; Sohvi Hörkkö; Hannu Kautiainen; Leena Arstila; Leena Laasonen; Elina Savolainen; Helena Niinisalo; Jarno Rutanen; Olga Marjoniemi; Mari Hämäläinen; Katriina Vuolteenaho; Eeva Moilanen; Oili Kaipiainen-Seppänen
Journal:  Ann Med       Date:  2020-02-10       Impact factor: 4.709

4.  Chronic uremia stimulates LDL carbamylation and atherosclerosis.

Authors:  Eugene O Apostolov; Debarti Ray; Alena V Savenka; Sudhir V Shah; Alexei G Basnakian
Journal:  J Am Soc Nephrol       Date:  2010-10-14       Impact factor: 10.121

5.  Carbamylated Low-Density Lipoprotein and Thrombotic Risk in Chronic Kidney Disease.

Authors:  W H Wilson Tang; Stanley L Hazen
Journal:  J Am Coll Cardiol       Date:  2016-10-11       Impact factor: 24.094

Review 6.  Modified low density lipoprotein and lipoprotein-containing circulating immune complexes as diagnostic and prognostic biomarkers of atherosclerosis and type 1 diabetes macrovascular disease.

Authors:  Alexander N Orekhov; Yuri V Bobryshev; Igor A Sobenin; Alexandra A Melnichenko; Dimitry A Chistiakov
Journal:  Int J Mol Sci       Date:  2014-07-21       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.